Economic evaluation of extended and conventional prophylaxis with enoxaparin against venous thromboembolism in patients undergoing surgery for abdominal cancer

References

• Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119: 132s–175s.
   Google Scholar
• Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine 2000; 160: 809–815.
   PubMed Web of Science ®Google Scholar
• Department of Health. Hospital Episode Statistics, 2002/03. Available at URL: http://www.dh.gov.uk/PublicationsAnd Statistics/Statistics/HospitalEpisode Statistics/HESFreeData/fs/en.
   Google Scholar
• British National Formulary (BNF). 43. March 2002. British Medical Association, Royal Pharmaceutical Society of Great Britain. 2002.
   Google Scholar
• Brown MC. An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy 1999; 45: 392–395.
   Google Scholar
• Monreal M, Roncales FJ, Ruiz J et al. Secondary prevention of venous thromboembolism: A role for low- molecular-weight heparin. Haemostasis 1998; 28: 236–243.
   PubMedGoogle Scholar
• Bergqvist D, Eldor A, Thorlacius-Ussing O et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomised multicentre trial with venographic assessment. British Journal of Surgery 1997; 84: 1099–1103.
   PubMed Web of Science ®Google Scholar
• Bergqvist D. Prolonged prophylaxis in postoperative medicine. Seminars in Thrombosis and Hemostasis 1997; 23: 149–154.
   Google Scholar
• Bergqvist D, Jonsson B. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement. Haemostasis 2000; 30 (Suppl. S2): 130–135.
   PubMedGoogle Scholar
• Dahl OE, Andreassen G, Aspelin T et al. Prolonged thromboprophylaxis following hip replacement surgery–results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis 1997; 77: 26–31.
   PubMed Web of Science ®Google Scholar
• Heit JA, Elliott CG, Trowbridge AA et al. Ardeparin sodium for extended out-of- hospital prophylaxis against venous thromboembolism after total hip or knee replacement. Archives of Internal Medicine 2000; 132: 853–861.
   Google Scholar
• Hull RD, Pineo GF, Francis C et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/ out-of-hospital placebo in hip arthroplasty patients. Archives of Internal Medicine 2000; 160: 2208–2215.
   Google Scholar
• Lassen MR, Borris LC, Anderson BS et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty–the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research 1998; 89: 281–287.
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Agnelli G, Cohen AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New England Journal of Medicine 2002; 346: 975–980.
   PubMed Web of Science ®Google Scholar
• Davies L, Richardson GA. Economic evaluation of enoxaparin as post discharge prophylaxis against deep-vein thrombosis in elective hip surgery. Value in Health 2000; 3: 397–406.
   PubMedGoogle Scholar
• Arcelus JI, Caprini JA, Motykie GD et al. Matching risk with treatment strategies in deep vein thrombosis management. Blood Coagulation and Fibrinolysis 1999; 10 (Suppl. 2): S37–S43.
   Google Scholar
• Oster G, Tuden RL, Colditz A. A cost effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopaedic surgery. Journal of the American Medical Association 1987; 257: 203–208.
   PubMed Web of Science ®Google Scholar
• Drummond M, Aristides M, Davies L et al. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. British Journal of Surgery 1994; 81: 1742–1746.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Aitleen JA, Hoffmeyer UK et al. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy. Pharmacoeconomics 1997; 12: 475–485.
   PubMedGoogle Scholar
• Lister-Sharp D, McDonagh M, Khan KS et al. A systematic review of the effectiveness and cost effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technology Assesment 2000; 4.
   Google Scholar
• Department of Health. NHS Reference Costs. http://www.doh.gov.uk/nhsexec/refcost s2001.htm. 2002.
   Google Scholar
• Netten A. The Unit Costs of Health and Social Care. PSSRU, 2002.
   Google Scholar
• Lloyd AC, Anderson PM, Quinlan DJ et al. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. Journal of Medical Economics 2001; 4: 99–113.
   Google Scholar
• Valette F, Hoffmeyer U, Lloyd A. Economic evaluation of the use of tinzaparin in the treatment of deep vein thrombosis. British Journal of Medical Economics 1995; 8: 111–123.
   Google Scholar
• Briggs AH. Handling uncertainty in cost- effectiveness models. Pharmacoeconomics 2000; 17: 479–500.
   PubMed Web of Science ®Google Scholar
• Rogers FB, Shackford SR, Ricci MA et al. Routine prophylactic vena cava filter insertion in severely injured trauma patients decreases the incidence of pulmonary embolism. Journal of the American College of Surgery 1995; 180: 641–647.
   PubMed Web of Science ®Google Scholar
• Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. British Medical Journal 2001; 323: 1300–1303.
   PubMed Web of Science ®Google Scholar